| Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind … JF Howard, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... The Lancet Neurology 16 (12), 976-986, 2017 | 594 | 2017 |
| Genome-wide analyses identify KIF5A as a novel ALS gene A Nicolas, KP Kenna, AE Renton, N Ticozzi, F Faghri, R Chia, ... Neuron 97 (6), 1267-1288, 2018 | 591 | 2018 |
| Über die Myasthenia gravis KE Osserman Klinische Wochenschrift 37 (1), 7-12, 1959 | 559 | 1959 |
| The MG Composite: a valid and reliable outcome measure for myasthenia gravis TM Burns, M Conaway, DB Sanders Neurology 74 (18), 1434-1440, 2010 | 245 | 2010 |
| Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review MK Hehir, LD Hobson-Webb, M Benatar, C Barnett, NJ Silvestri, ... Neurology 89 (10), 1069-1077, 2017 | 213 | 2017 |
| Clinical findings in MuSK‐antibody positive myasthenia gravis: a US experience M Pasnoor, GI Wolfe, S Nations, J Trivedi, RJ Barohn, L Herbelin, ... Muscle & Nerve: Official Journal of the American Association of …, 2010 | 213 | 2010 |
| Guillain-barré syndrome TM Burns Seminars in neurology 28 (02), 152-167, 2008 | 213 | 2008 |
| Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis JF Howard Jr, V Bril, TM Burns, R Mantegazza, M Bilinska, A Szczudlik, ... Neurology 92 (23), e2661-e2673, 2019 | 205 | 2019 |
| Vasculitic neuropathies KG Gwathmey, TM Burns, MP Collins, PJB Dyck The Lancet Neurology 13 (1), 67-82, 2014 | 205 | 2014 |
| Less is more, or almost as much: a 15‐item quality‐of‐life instrument for myasthenia gravis TM Burns, MR Conaway, GR Cutter, DB Sanders, Muscle Study Group Muscle & nerve 38 (2), 957-963, 2008 | 194 | 2008 |
| Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis S Muppidi, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... Muscle & nerve 60 (1), 14-24, 2019 | 190 | 2019 |
| Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial GI Wolfe, HJ Kaminski, IB Aban, G Minisman, HC Kuo, A Marx, P Ströbel, ... The Lancet Neurology 18 (3), 259-268, 2019 | 180 | 2019 |
| Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS M Benatar, L Zhang, L Wang, V Granit, J Statland, R Barohn, A Swenson, ... Neurology 95 (1), e59-e69, 2020 | 156 | 2020 |
| Multipoint incremental motor unit number estimation as an outcome measure in ALS JM Shefner, ML Watson, L Simionescu, JB Caress, TM Burns, ... Neurology 77 (3), 235-241, 2011 | 156 | 2011 |
| Recommendations for myasthenia gravis clinical trials M Benatar, DB Sanders, TM Burns, GR Cutter, JT Guptill, F Baggi, ... Muscle & nerve 45 (6), 909-917, 2012 | 151 | 2012 |
| Quality of life and measures of quality of life in patients with neuromuscular disorders TM Burns, CD Graham, MR Rose, Z Simmons Muscle & nerve 46 (1), 9-25, 2012 | 148 | 2012 |
| Mycophenolate mofetil in AChR‐antibody‐positive myasthenia gravis: outcomes in 102 patients MK Hehir, TM Burns, J Alpers, MR Conaway, M Sawa, DB Sanders Muscle & Nerve: Official Journal of the American Association of …, 2010 | 145 | 2010 |
| Electrical impedance myography as a biomarker to assess ALS progression SB Rutkove, JB Caress, MS Cartwright, TM Burns, J Warder, WS David, ... Amyotrophic Lateral Sclerosis 13 (5), 439-445, 2012 | 141 | 2012 |
| Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials SC Apfel, AK Asbury, V Bril, TM Burns, JN Campbell, CH Chalk, PJ Dyck, ... Journal of the neurological sciences 189 (1-2), 3-5, 2001 | 138 | 2001 |
| Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite TM Burns, MR Conaway, GR Cutter, DB Sanders Muscle & Nerve: Official Journal of the American Association of …, 2008 | 134 | 2008 |
